| ID Source | ID |
|---|---|
| PubMed CID | 12443 |
| CHEMBL ID | 1406645 |
| CHEBI ID | 189155 |
| SCHEMBL ID | 194752 |
| MeSH ID | M0065911 |
| Synonym |
|---|
| AC-20491 |
| q8e543qkmk , |
| ec 211-185-4 |
| 5-17-11-00265 (beilstein handbook reference) |
| unii-q8e543qkmk |
| smr001224535 |
| MLS002152941 |
| dion 6692 |
| fg 4000 |
| tetrabromophthalic anhydride |
| 632-79-1 |
| nsc4874 |
| firemaster pht 4 |
| bromphthal |
| nsc-4874 |
| phthalic anhydride, tetrabromo- |
| 1, 4,5,6,7-tetrabromo- |
| 3,5,6-tetrabromophthalic anhydride |
| 1,3-isobenzofurandione, 4,5,6,7-tetrabromo- |
| 4,5,6,7-tetrabromo-2-benzofuran-1,3-dione |
| NCGC00091664-01 |
| brn 0018908 |
| saytex rb 49 |
| dion 6692 (van) |
| bromophthal |
| phthalic acid, tetrabromo-, anhydride |
| hsdb 5438 |
| nsc 4874 |
| 3,4,5,6-tetrabromophthalic anhydride |
| pht 4 |
| ccris 6201 |
| einecs 211-185-4 |
| fg 400 |
| tetrabromophthalic acid anhydride |
| tetrabromophthalic anhydride, 98% |
| NCGC00091664-02 |
| FT-0656322 |
| T0046 |
| CHEBI:189155 |
| 4,5,6,7-tetrabromo-2-benzouran-1,3-dione |
| AKOS002664700 |
| 4,5,6,7-tetrabromoisobenzofuran-1,3-dione |
| A834308 |
| NCGC00091664-03 |
| 4,5,6,7-tetrabromo-1,3-isobenzofurandione |
| HMS3039C07 |
| cas-632-79-1 |
| dtxsid6026084 , |
| NCGC00257610-01 |
| tox21_200056 |
| dtxcid606084 |
| firemaster pht4 |
| 3,4,5,6-tetrabromophthalic anhydride [hsdb] |
| SCHEMBL194752 |
| T3871 |
| saytex rb-49 |
| 4,5,6,7-tetrabromo-2-benzofuran-1,3-dione # |
| great lakes pht4 |
| CHEMBL1406645 |
| BR1206 |
| mfcd00005919 |
| AS-11805 |
| 5-(4-acetyl-benzoylamino)-2-ethoxy-benzenesulfonylchloride |
| AMY37019 |
| Q27287114 |
| D95386 |
| tetrabromphthalsa currencyure-anhydrid |
| tetrabromo-1,3-dihydro-2-benzofuran-1,3-dione |
| tetrabromophthalic anhydride (purified by sublimation) |
| EN300-28795 |
| Class | Description |
|---|---|
| cyclic dicarboxylic anhydride | An acid anhydride derived by loss of water between two carboxylic groups in the same molecule so as to close a ring. |
| 2-benzofurans | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 89.1251 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| AR protein | Homo sapiens (human) | Potency | 43.1604 | 0.0002 | 21.2231 | 8,912.5098 | AID588516; AID743035; AID743063 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 39.8107 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 68.4501 | 0.0010 | 22.6508 | 76.6163 | AID1224893 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 2.0219 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743079 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 67.7069 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 61.0063 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 1.3333 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||